We are pleased to announce that we are now analytically validating the Illumina TruSight® Tumor 170 cancer mutation panel. The assay will be CLIA compliant and CE marked for prospective use in clinical trials from January 2018.

Almac Diagnostics are investing in the validation of this panel and will be in a position to provide validation data by the end of 2017 to interested parties.

“This assay will provide Pharmaceutical and Biotech companies with a new option in the marketplace to support their clinical trials and CDx development.”

We are encouraging Pharma and Biotech Companies to get in touch with us now to discuss their future clinical trial requirements.

Almac Diagnostics already offer Illumina TruSight® Tumor 170 as a research use only (RUO) assay.

Almac Diagnostics Testing

Almac Diagnostics were selected as one of Illumina's key Beta Test sites for TruSight Tumor® 170. This facilitated early access prior to commercial release. We have built up a vast amount of experience with the assay that Pharma and Biotech partners can benefit from.

Validated Assay Available January 2018

The Assay

The Illumina TruSight® Tumor 170 panel is a Next Generation Sequencing (NGS) assay that targets DNA and RNA variants from the same sample.
The assay covers 170 common cancer genes including key actionable mutations across multiple cancers.

Further information, including the full list of cancer genes, can be found on the Illumina website data sheet.

View Data sheet

At a Glance

  • Illumina enrichment based targeted NGS panel run on the NextSeq500 and NextSeq550
  • Covers 170 genes associated with common solid tumors
  • Compatible with FFPE tissue and simultaneously analyses both RNA and DNA from a single sample
  • Targets all coding exons in 170 genes including 55 genes for fusions and splice variants, 148 for SNVs and Indels, and 59 genes for CNV
  • Capable of detecting somatic mutations as low as 5% mutant allele frequency, with >95% sensitivity and specificity

Key Benefits

  • Evaluate multiple biomarkers on one panel from one sample
  • Works from minimal tissue inputs
  • Rapid turnaround time
  • Access to raw data
  • Powerful reporting and interpretation of data
  • A highly competitive price
  • A solution that will be kit-able in future to support multiple CDx tests

Key Facts

Metric Almac Dx TruSight® Tumor 170
Sample Input Requirement - DNA & RNA 40-120ng DNA
40-85ng RNA*
Sample Input Requirement - Tissue ≥ 2mm³ tissue from 8 FFPE tissue sections ∞
Turnaround Time 9 days §
Customisable Content Yes
Raw Data Provided with Report Yes

*Ability of TST-170 to analyse RNA alows for detection of expressed fusion genes resulting from both chromosomal abnormalities and posttranscriptional events and thus detects gene fusions that DNA sequencing panels would not recognize. ∞ Variable across tissue type; Melanoma would require more tissue; Tissue fixation has greatest influence upon sample QC and assay performance. § From sample receipt, inclusive of pathology review

Almac Diagnostics Testing

Complimentary Webinar

Almac Diagnostics - Illumina TruSight® Tumor 170 – Validated Assay: Enabling Biomarker Led Clinical Trials and CDx Development.

14th November

11am EST | 4pm GMT | 5pm CET

Sign up today

In the Press


Almac Diagnostics and EORTC Establish Collaboration for Tumour Molecular Profiling using Illumina TruSight® Tumor 170 panel


Illumina interview Almac Diagnostics on leveraging TruSight® Tumor 170 and being a key beta test site for the panel


Almac Diagnostics will be attending World CDx USA in Boston from 17th-19th October.

Dr Katarina Wikstrom will be speaking on “NGS Panels – From Patient Selection to CDx.” Dr Wikstrom will be talking about Almac Diagnostics use of Illumina TruSight® Tumor 170 panel, both for RUO use and about our current validation of the panel towards CLIA compliance and CE marking for prospective use in Clinical Trials.

We will also have our US Business Development staff onsite at World CDx Boston. If you would like to set up a meeting at this event to talk about the Illumina TruSight® Tumor 170 cancer mutation panel, click on the link below.

Event Info

Contact Us